Summit Therapeutics (SMMT) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Viatris (VTRS) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 76.6% versus a loss of 22.3%. Over five years, SMMT leads with a +241.6% price change compared with +31.1% for VTRS. Viatris is the larger company by market cap ($20.26 billion vs $14.03 billion), about 1.4 times the size.
Viatris pays a dividend yielding 2.72%, while Summit Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SMMT | VTRS |
|---|---|---|
| Share price | $17.59 | $17.64 |
| Market cap | $14.03B | $20.26B |
| 1-day change | +2.45% | +1.15% |
| YTD return | +0.57% | +41.69% |
| 1-year return | -22.34% | +76.58% |
| 5-year return | +241.55% | +31.05% |
| Forward P/E | — | 6.60 |
| EPS (TTM) | $-1.14 | $-0.36 |
| Dividend yield | 0.00% | 2.72% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | — | $14.30B |
| Revenue growth (YoY) | — | -2.98% |
| Net income (latest FY) | $-1.08B | $-3.51B |
| Gross margin | — | 35.06% |
| Operating margin | — | -18.62% |
| Net margin | — | -24.58% |
| 52-week high | $29.23 | $18.43 |
| 52-week low | $12.07 | $9.73 |
| Distance from 52-week high | -39.82% | -4.29% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +69.30% | +11.68% |
| Average volume | 5.87M | 9.28M |
| Shares outstanding | 797.75M | 1.15B |
| Employees | 265 | 30,000 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed SMMT by 98.9 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.72% vs 0.00%).
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Healthcare · Biotechnology · 265 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Healthcare · Drug Manufacturers - Specialty & Generic · 30,000 employees
SMMT vs VTRS FAQ
Which is bigger, Summit Therapeutics or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $20.26B compared with $14.03B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, SMMT or VTRS?
VTRS returned +76.58% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Summit Therapeutics or Viatris?
Viatris pays a dividend yielding 2.72%, while Summit Therapeutics does not currently pay a regular dividend.
Are Summit Therapeutics and Viatris in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Summit Therapeutics and Drug Manufacturers - Specialty & Generic for Viatris.